EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration

Eve Karloski iD, Beth Dudley iD, Brenda Diergaarde, Amie Blanco, Jessica N Everett iD, Elana Levinson, Tara Rangarajan, Peter P Stanich, Kimberly Childers, Sandra Brown, Christine Drogan iD, Giulia Martina Cavestro und 13 weitere

Cancer · 2024

DOI: 10.1002/cncr.35383 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Cancer, 2024. Verfasst von Eve Karloski und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Germ-Line Mutation, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Genetic Predisposition to Disease. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pancreatic ductal adenocarcinoma (PDAC) surveillance is recommended for some individuals with a pathogenic or likely pathogenic variant (PV/LPV) in a PDAC susceptibility gene; the recommendation is often dependent on family history of PDAC. This study aimed to describe PDAC family history in individuals with PDAC who underwent genetic testing to determine the appropriateness of including a family history requirement in these recommendations.

Methods

Individuals with PDAC with a germline heterozygous PV/LPV in ATM , BRCA1 , BRCA2 , EPCAM , MLH1 , MSH2 , MSH6 , PALB2 , or PMS2 (PV/LPV carriers) were assessed for family history of PDAC in first‐degree relatives (FDRs) or second‐degree relatives (SDRs) from nine institutions. A control group of individuals with PDAC without a germline PV/LPV was also assessed.

Results

The study included 196 PV/LPV carriers and 1184 controls. In the PV/LPV carriers, 25.5% had an affected FDR and/or SDR compared to 16.9% in the control group ( p = .004). PV/LPV carriers were more likely to have an affected FDR compared to the controls ( p = .003) but there was no statistical difference when assessing only affected SDRs ( p = .344).

Conclusions

Most PV/LPV carriers who developed PDAC did not have a close family history of PDAC and would not have met most current professional societies’ recommendations for consideration of PDAC surveillance before diagnosis. However, PV/LPV carriers were significantly more likely to have a family history of PDAC, particularly an affected FDR. These findings support family history as a risk modifier in PV/LPV carriers, and highlight the need to identify other risk factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationPancreatic NeoplasmsCarcinoma, Pancreatic DuctalGenetic Predisposition to DiseaseGenetic TestingHumansFemaleMaleMiddle AgedAgedAdultMedical History TakingHeterozygoteCase-Control StudiesAged, 80 and over

Stichwörter der Autor:innen

genetic testinggermline mutationpancreatic cancerrisk factors

Autor:innen und Institutionen

  • Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Department of Human Genetics, University of Pittsburgh and Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
  • Cancer Genetics and Prevention Program, University of California San Francisco, San Francisco, California, USA.
  • Department of Medicine, New York University Langone Health, New York, New York, USA.
  • Department of Medicine, Columbia University Irving Medical Center, New York, New York, USA.
  • Nancy and James Grosfeld Cancer Genetics Center, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.

ORCID-Profile: Eve Karloski, Beth Dudley, Jessica N Everett, Christine Drogan, Sonia S Kupfer

Förderung

  • NCI NIH HHS

Zitieren

APA

Karloski, E., Dudley, B., Diergaarde, B., Blanco, A., Everett, J. N., Levinson, E., Rangarajan, T., Stanich, P. P., Childers, K., Brown, S., Drogan, C., Cavestro, G. M., Gordon, K., Singh, A., Simeone, D. M., Reich, H., Kastrinos, F., Zakalik, D., Hampel, H., …, & Brand, R. E. (2024). The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Cancer. https://doi.org/10.1002/cncr.35383

Vancouver

Karloski E, Dudley B, Diergaarde B, Blanco A, Everett JN, Levinson E, et al. The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration. Cancer. 2024. doi:10.1002/cncr.35383

BibTeX
@article{Karloski2024,
  author = {Karloski, Eve and Dudley, Beth and Diergaarde, Brenda and Blanco, Amie and Everett, Jessica N and Levinson, Elana and Rangarajan, Tara and Stanich, Peter P and Childers, Kimberly and Brown, Sandra and Drogan, Christine and Cavestro, Giulia Martina and Gordon, Kelly and Singh, Aparajita and Simeone, Diane M and Reich, Hannah and Kastrinos, Fay and Zakalik, Dana and Hampel, Heather and Pearlman, Rachel and Gordon, Ora K and Kupfer, Sonia S and Puzzono, Marta and Zuppardo, Raffaella Alessia and Brand, Randall E},
  title = {The role of family history in predicting germline pathogenic variant carriers who develop pancreatic cancer: Results of a multicenter collaboration},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35383}
}
Kostenlos starten →